Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukaemia (AML). Informative recombination events in 6 FPD/AML pedigrees with evidence of linkage to markers on chromosome 21q identified an 880-kb interval containing the disease gene. Mutational analysis of regional candidate genes showed nonsense mutations or intragenic deletion of one allele of the haematopoietic transcription factor CBFA2 (formerly AML1) that co-segregated with the disease in four FPD/AML pedigrees. We identified heterozygous CBFA2 missense mutations that co-segregated with the disease in the remaining two FPD/AML pedigrees at phylogenetically conserved amino acids R166 and R201, respectively. Analysis of bone marrow or peripheral blood cells from affected FPD/AML individuals showed a decrement in megakaryocyte colony formation, demonstrating that CBFA2 dosage affects megakaryopoiesis. Our findings support a model for FPD/AML in which haploinsufficiency of CBFA2 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The transcription factor RUNX-1 plays a key role in megakaryocyte differentiation and is mutated in cases of myelodysplastic syndrome and leukemia.”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
In the citing paper
“Germ line mutations in RUNX-1 cause familial platelet disorder with the propensity to develop acute myelogenous leukemia (FPD/AML), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet defects and a high incidence of developing myelodysplastic syndrome (MDS) and leukemia”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
Citations
Cites
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355 · cited 1×
“Fusion of PDGF Receptor β to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.”
BackgroundWang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Self-citationGolub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationOncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis.
Weinberg, R. A. (1989) · PubMed · Cited by 949
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732 · cited 1×
“; the CBFB / MYH11 fusion associated with inv(16) myelomonocytic leukaemia with eosinophili”
BackgroundFusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray-Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., & Gilliland, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4917 · Cited by 704
Self-citationShivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J. M., & Orkin, S. H. (1995) · Cell · doi:10.1016/0092-8674(95)90531-6 · Cited by 693 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
BackgroundShivdasani, R. A., Fujiwara, Y., McDevitt, M. A., & Orkin, S. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3965 · Cited by 674 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
Background
Cited by
Items 101–200 of 1,000
Requirement of Runx1/AML1/PEBP2αB for the generation of haematopoietic cells from endothelial cells
Yokomizo, T., Ogawa, M., Osato, M., Kanno, T., Yoshida, H., Fujimoto, T., Fraser, S., Nishikawa, S., Okada, H., Satake, M., et al. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00393.x · Cited by 176
“The Runt-domain family transcription factors are known to show a gene dosage effect at the stage where these factors actually play a critical role: Drosophila runt in sex determination, RUNX2 in bone formation, and RUNX1 in leukaemia (Duffy & Gergen 1991; Otto et al. 1997; Song et al. 1999).”
BackgroundBaldus, C. D., Liyanarachchi, S., Mrózek, K., Auer, H., Tanner, S. M., Guimond, M., Ruppert, A. S., Mohamed, N., Davuluri, R. V., Caligiuri, M. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400272101 · Cited by 173
A proximal activator of transcription in epithelial-mesenchymal transition
Venkov, C. D., Link, A. J., Jennings, J. L., Plieth, D., Inoue, T., Nagai, K., Xu, C., Dimitrova, Y. N., Rauscher, F. J., & Neilson, E. G. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29544 · Cited by 170
“Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.”
BackgroundWiley, J. S., Dao-Ung, L. P., Gu, B. J., Sluyter, R., Shemon, A. N., Li, C., Taper, J., Gallo, J., & Manoharan, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08156-4 · Cited by 166
Advances in germline predisposition to acute leukaemias and myeloid neoplasms
Klco, J. M., & Mullighan, C. G. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00315-z · Cited by 153
Rubnitz, J. E., Gibson, B., & Smith, F. O. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.008 · Cited by 158
“This multistep mechanism for the pathogenesis of AML is supported by murine models,(48,49) the analysis of leukemia in twins, and the analysis of patients who have FDP/AML syndrome.(54) Mutations in a number of genes that confer a proliferative and/or survival advantage to cells but do not affect differentiation (Clas…”
From hematopoietic stem cells to platelets
Chang, Y., Bluteau, D., Debili, N., & Vainchenker, W. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02472.x · Cited by 198
Smith, M., Barnett, M., Bassan, R., Gatta, G., Tondini, C., & Kern, W. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.11.002 · Cited by 162
“There are recognised autosomal dominant and recessive cases of familial AML [12,13] in addition to associations with a variety of genetic syndromes including trisomy 21 [14] and those characterised by defective DNA repair (eg Fanconi’s anaemia, ataxia telangiectasia and Bloom’s syndrome) [15].”
BackgroundKeel, S. B., Scott, A., Sanchez-Bonilla, M., Ho, P. A., Gulsuner, S., Pritchard, C. C., Abkowitz, J. L., King, M.-C., Walsh, T., & Shimamura, A. (2016) · Haematologica · doi:10.3324/haematol.2016.149476 · Cited by 159
“Physical anomalies, percent (n) 24% (23) 21% (3)”
Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome
Gurbuxani, S., Vyas, P., & Crispino, J. D. (2004) · Blood · doi:10.1182/blood-2003-05-1556 · Cited by 166
NBS1 Is a Prostate Cancer Susceptibility Gene
Cybulski, C., Górski, B., Dębniak, T., Gliniewicz, B., Mierzejewski, M., Masojć, B., Jakubowska, A., Matyjasik, J., Złowocka, E., Sikorski, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2502 · Cited by 156
Zusso, M., Methot, L., Lo, R., Greenhalgh, A. D., David, S., & Stifani, S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6182-11.2012 · Cited by 163
“We first took advantage of the previous demonstration that Runx1 heterozygosity is haploinsufficient in the myeloid lineage (Song et al., 1999; Cai et al., 2000) to test whether reduced Runx1 activity would perturb microglial cell proliferation in vivo.”
BackgroundGermline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia
Topka, S., Vijai, J., Walsh, M. F., Jacobs, L., Maria, A., Villano, D., Gaddam, P., Wu, G., McGee, R. B., Quinn, E., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005262 · Cited by 159
“Genes associated with these syndromes include RUNX1, ANKRD26, GATA1,MPL,HOXA11 and RMB8A[9–16].”
BackgroundThe leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp.
Bravo, J., Li, Z., Speck, N. A., & Warren, A. J. (2001) · Nature Structural Biology · doi:10.1038/86264 · Cited by 169
Self-citationKuo, M.-C., Liang, D.-C., Huang, C.-F., Shih, Y.-S., Jh, W., Lin, T.-L., & Shih, L.-Y. (2009) · Leukemia · doi:10.1038/leu.2009.48 · Cited by 174
Harada, H., Harada, Y., Tanaka, H., Kimura, A., & Inaba, T. (2003) · Blood · doi:10.1182/blood-2002-04-1010 · Cited by 157
“The numbers in the left-hand column indicate the case numbers (1-13) described in Tables 2, 3, and 4.”
MethodDastugue, N. (2002) · Blood · doi:10.1182/blood-2001-12-0241 · Cited by 163
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants
Luo, X., Feurstein, S. K., Mohan, S., Porter, C. C., Jackson, S. A., Keel, S., Chicka, M. C., Brown, A. L., Kesserwan, C. A., Agarwal, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000644 · Cited by 165
“Germline PATH variants in RUNX1, first described in 1999, cause dominantly inherited familial platelet disorder with a predisposition to acute myeloid leukemia (FPD/AML), characterized by mild to moderate thrombocytopenia, functional and ultrastructural platelet defects, and a predisposition to myelodysplastic syndrom…”
BackgroundSelf-citationFamilial myelodysplastic syndromes: a review of the literature
Liew, E., & Owen, C. (2011) · Haematologica · doi:10.3324/haematol.2011.043422 · Cited by 158
“Shinawi(31) F 9 months No Yes Yes Hypertelorism, epicanthal folds, flat del(21)(q21.”
BackgroundInfluentialHarewood, L., Robinson, H. M., Harris, R., Al-Obaidi, M. J., Jalali, G. R., Martineau, M., Moorman, A. V., Sumption, N. D., Richards, S. M., Mitchell, C., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402849 · Cited by 158
Yoshida, T., Kanegane, H., Osato, M., Yanagida, M., Miyawaki, T., Ito, Y., & Shigesada, K. (2002) · The American Journal of Human Genetics · doi:10.1086/342717 · Cited by 159
“More-over, a converse situation occurs in RUNX1, in which recurrent mutations have been reported for the R214-equivalent residue encoded by CGA, whereas no mutation has been detected at the R179-equivalent residue encoded by AGA (Osato et al. 1999; Song et al. 1999; Preudhomme et al. 2000).”
BackgroundBrown, A. L., Arts, P., Carmichael, C. L., Babic, M., Dobbins, J., Chong, C.-E., Schreiber, A. W., Feng, J., Phillips, K., Wang, P. P. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000901 · Cited by 155
“He had no ancestral family history of thrombocytopenia or HMs. WES identified an intronic RUNX1 c.968-10C.A variant that was predicted to generate a cryptic splice acceptor generating a transcript encoding p.A324Lfs*7, which confirmed through RNA studies (supplemental Figure 9).”
BackgroundInfluentialImai, Y., Kurokawa, M., Izutsu, K., Hangaishi, A., Takeuchi, K., Maki, K., Ogawa, S., Chiba, S., Mitani, K., & Hirai, H. (2000) · Blood · doi:10.1182/blood.v96.9.3154 · Cited by 154
AML1 mutations induced MDS and MDS/AML in a mouse BMT model
Watanabe-Okochi, N., Kitaura, J., Ono, R., Harada, H., Harada, Y., Komeno, Y., Nakajima, H., Nosaka, T., Inaba, T., & Kitamura, T. (2008) · Blood · doi:10.1182/blood-2007-01-068346 · Cited by 150
The Runx genes: lineage-specific oncogenes and tumor suppressors
Cameron, E. R., & Neil, J. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207130 · Cited by 167
“Moreover, RUNX1 loss of function mutations underlie familial platelet disorder, a syndrome which features predisposition to myeloid leukemia (Song et al., 1999).”
BackgroundMegakaryocyte biology and related disorders
Pang, L., Weiss, M. J., & Poncz, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26720 · Cited by 183
Self-citationDella Gatta, G., Palomero, T., Perez-Garcia, A., Ambesi-Impiombato, A., Bansal, M., Carpenter, Z. W., De Keersmaecker, K., Sole, X., Xu, L., Paietta, E., et al. (2012) · Nature Medicine · doi:10.1038/nm.2610 · Cited by 150
Klimchenko, O., Mori, M., Stefano, A. D., Langlois, T., Larbret, F., Lécluse, Y., Feraud, O., Vainchenker, W., Norol, F., & Debili, N. (2009) · Blood · doi:10.1182/blood-2008-09-178863 · Cited by 167
Perspectives onRUNXgenes: An update
Cohen, M. M. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33021 · Cited by 181
“RUNX1 dosage affects megakaryopoiesis [Song et al., 1999].”
BackgroundCbfβ-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia
Kuo, Y., Landrette, S. F., Heilman, S. A., Perrat, P. N., Garrett, L. J., Liu, P. P., Beau, M. M. L., Kogan, S. C., & Castilla, L. H. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.014 · Cited by 159
APC/CTNNB1 (β‐catenin) pathway alterations in human prostate cancers
Gerstein, A. V., Almeida, T. A., Zhao, G., Chess, E., Shih, I., Buhler, K., Pienta, K., Rubin, M. A., Vessella, R., & Papadopoulos, N. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10037 · Cited by 151
“Haploinsufficiency of the CBFA2 gene has been implicated as the cause of familial thrombocytopenia, a syndrome with a propensity to the development of acute myeloid leukemia (Song et al., 1999).”
BackgroundLevanon, D., Glusman, G., Bangsow, T., Ben‐Asher, E., Male, D. A., Avidan, N., Bangsow, C., Hattori, M., Taylor, T. D., Taudien, S., et al. (2001) · Gene · doi:10.1016/s0378-1119(00)00532-1 · Cited by 172
“12 belongs to the `runt domain' gene family of transcription factors (also known as AML/ CBFA/PEBP2a).”
BackgroundResultInfluentialThe genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
Raza, A., & Galili, N. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3321 · Cited by 170
Niemeyer, C. M., & Kratz, C. P. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06958.x · Cited by 155
“Heterozygous germline mutations of the transcription factor gene RUNX1 (also known as AML1), which is a common target for chromosomal translocation in acute leukaemia, cause familial thrombocytopenia with a propensity to develop acute myelogenous leukaemia (Song et al, 1999).”
BackgroundCancer Genomics and Inherited Risk
Stadler, Z. K., Schrader, K. A., Vijai, J., Robson, M. E., & Offit, K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7271 · Cited by 146
“Inherited predisposition to myelodysplastic syndrome/AML had previouslybeenlinkedtomutationswithinhematopoietictranscriptionfactors RUNX1 and CEBPA.(71,72) NGS studies linked mutations of the transcription factor GATA2 to familial AML and, occasionally, Emberger syndrome, an autosomal-dominant primary lymphedema assoc…”
BackgroundGermline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies
Saliba, J., Saint‐Martin, C., Stefano, A. D., Lenglet, G., Marty, C., Keren, B., Pasquier, F., Della-Valle, V., Secardin, L., Leroy, G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3380 · Cited by 150
“Arg686Ser 45,XY,–5,der(6)t(6;8) (p22;q21), –17+mar(16)/ 46,XY[1] F1 III-4 Male ET 35.”
Phosphorylation, acetylation and ubiquitination: The molecular basis of RUNX regulation
Bae, S., & Lee, Y. H. (2005) · Gene · doi:10.1016/j.gene.2005.10.017 · Cited by 161
New mechanisms of AML1 gene alteration in hematological malignancies
Roumier, C., Fenaux, P., Lafage‐Pochitaloff, M., Imbert, M., Éclache, V., & Preudhomme, C. (2003) · Leukemia · doi:10.1038/sj.leu.2402766 · Cited by 159
RUNX3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder Tumors
Kim, W.-J., Kim, E.-J., Jeong, P., Quan, C., Kim, J., Li, Q.-L., Yang, J.-O., Ito, Y., & Bae, S.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1647 · Cited by 144
“For example, heterozygous loss-of-function mutation of RUNX3 is associated with familial platelet disorder with predisposition to acute myeloid leukemia (44).”
BackgroundPathophysiology of Acute Myeloid Leukemia
Wachter, F., & Pikman, Y. (2024) · Acta Haematologica · doi:10.1159/000536152 · Cited by 159
THE GENETICS OF PSORIASIS AND AUTOIMMUNITY
Bowcock, A. M. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162324 · Cited by 161
Inherited platelet disorders: toward DNA-based diagnosis
Lentaigne, C., Freson, K., Laffan, M., Turro, E., & Ouwehand, W. H. (2016) · Blood · doi:10.1182/blood-2016-03-378588 · Cited by 159
Advances in our understanding of the molecular basis of disorders of platelet function
Nurden, A. T., & Nurden, P. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04274.x · Cited by 157
Translational implications of somatic genomics in acute myeloid leukaemia
Meyer, S. C., & Levine, R. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70008-7 · Cited by 161
The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells
Lacorazza, H. D., Yamada, T., Liu, Y., Miyata, Y., Sivina, M., Nunes, J., & Nimer, S. D. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.017 · Cited by 141
Qualitative disorders of platelets and megakaryocytes
Nurden, A. T. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01428.x · Cited by 141
North, T. E., Stacy, T., Matheny, C. J., Speck, N. A., & de Bruijn, M. F. T. R. (2004) · STEM CELLS · doi:10.1634/stemcells.22-2-158 · Cited by 133
Self-citationGenome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes
Gelsi-Boyer, V., Trouplin, V., Adélaïde, J., Aceto, N., Remy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires-Alj, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-299 · Cited by 126
“RUNX1 encodes the DNA-binding, alpha subunit of the core binding factor (CBF) and is viewed as a tumor suppressor gene whose haplo-insufficiency or dominant-negative mutations play a role in leukemogenesis [35,36].”
Regulation of megakaryocyte maturation and platelet formation
Bluteau, D., Lordier, L., Stefano, A. D., Chang, Y., Raslová, H., Debili, N., & Vainchenker, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03398.x · Cited by 172
Lorsbach, R. B., Moore, J., Ang, S. O., Sun, W., Lenny, N., & Downing, J. R. (2004) · Blood · doi:10.1182/blood-2003-07-2439 · Cited by 130
Integrative analysis of RUNX1 downstream pathways and target genes
Michaud, J., Simpson, K. M., Escher, R., Buchet-Poyau, K., Beissbarth, T., Carmichael, C., Ritchie, M. E., Schütz, F., Cannon, P., Liu, M., et al. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-363 · Cited by 136
“In addition to somatic alterations, germ-line point mutations in RUNX1 are responsible for an autosomal dominant platelet disorder with a propensity to develop leukemia (FPD-AML, OMIM 601399) [9,10].”
BackgroundAdvances in understanding the genetic basis for bone-marrow failure
Lieberman, L., & Dror, Y. (2006) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000192520.48411.fa · Cited by 137
Buijs, A., Poddighe, P., van Wijk, R., van Solinge, W., Borst, E., Verdonck, L., Hagenbeek, A., Pearson, P., & Lokhorst, H. (2001) · Blood · doi:10.1182/blood.v98.9.2856 · Cited by 135
“II:1 Dec 1998 46,XY No 1 21 II:3 Dec 1998 46,XX BT II:4 Aug 1996 AML M1 92,XXYY, add(7)(q31), add(7)(q31)[14]/46,XY[10] Apr 1997 After BMT 46,XX Nov 1997 After BMT Sep 1998 Relapse/secondary leukemia? 47,XX,121[13]/47,XX,18[7]/46,XX[4] 1 21 (37%) II:7 Oct 1996 Donor 46,XX Oct 1998 MDS 46,XX BT Feb 1999 AML M1 46,XX BT…”
BackgroundChristiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2004) · Blood · doi:10.1182/blood-2004-02-0754 · Cited by 135
KLF5 is frequently deleted and down‐regulated but rarely mutated in prostate cancer
Chen, C., Bhalala, H. V., Vessella, R. L., & Dong, J. (2003) · The Prostate · doi:10.1002/pros.10205 · Cited by 135
“Haploinsufficiency is one mechanismunderlyinghumangenetic diseases [16,17].”
Grisolano, J. L., O’Neal, J., Cain, J., & Tomasson, M. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1531730100 · Cited by 152
Geddis, A. E. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.03.001 · Cited by 163
Cooperating cancer-gene identification through oncogenic-retrovirus–induced insertional mutagenesis
Du, Y., Spence, S. E., Jenkins, N. A., & Copeland, N. G. (2005) · Blood · doi:10.1182/blood-2004-12-4840 · Cited by 133
Fodde, R., & Smits, R. (2002) · Science · doi:10.1126/science.1077707 · Cited by 132
The Proto-Oncogene ERG in Megakaryoblastic Leukemias
Rainis, L., Toki, T., Pimanda, J. E., Rosenthal, E., Machol, K., Strehl, S., Göttgens, B., Ito, E., & Izraeli, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0147 · Cited by 139
“(12, 13) and overexpression facilitates megakaryocytic differentiation (10).”
Pozner, A., Goldenberg, D., Negreanu, V., Le, S.-Y., Elroy-Stein, O., Levanon, D., & Groner, Y. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2297-2307.2000 · Cited by 127
“The observed modulation of AML1 expression during differentiation of K562 may be related to the more recent finding that haploinsufficiency of AML1 impairs megakaryopoiesis (60).”
BackgroundCooperation between the GATA and RUNX factors Serpent and Lozenge during Drosophila hematopoiesis.
Waltzer, L., Ferjoux, G., Bataille, L., & Haenlin, M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg622 · Cited by 129
RUNX: A trilogy of cancer genes
Lund, A. H., & van Lohuizen, M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00049-1 · Cited by 140
Dyskeratosis congenita: telomerase, telomeres and anticipation
Marrone, A., Walne, A. J., & Dokal, I. S. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.04.004 · Cited by 134
Zhang, M. Y., Keel, S. B., Walsh, T., Lee, M. K., Gulsuner, S., Watts, A. C., Pritchard, C. C., Salipante, S. J., Jeng, M. R., Hofmann, I., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.113456 · Cited by 122
“Heterozygous RUNX1 mutations cause familial platelet disorder with propensity to myeloid malignancy.(28,29) RUNX1 p.”
BackgroundA role for RUNX1 in hematopoiesis and myeloid leukemia
Ichikawa, M., Yoshimi, A., Nakagawa, M. M., Nishimoto, N., Watanabe‐Okochi, N., & Kurokawa, M. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1347-3 · Cited by 144
Burns, C. E., DeBlasio, T., Zhou, Y., Zhang, J., Zon, L. I., & Nimer, S. D. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00955-4 · Cited by 133
Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant‐negative, or hypomorphic alleles
Matheny, C., Speck, M. E., Cushing, P. R., Zhou, Y., Corpora, T., Regan, M. C., Newman, M. N., Roudaia, L., Speck, C. L., Gu, T.-L., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601568 · Cited by 131
“…al (2002); (6) Osato et al (1999); (7) Michaud et al (2002); (8) Walker et al (2002); (9) Preudhomme et al (2000); (10) Roumier et al (2003); (11) Song et al (1999); (12) Buijs et al (2001). cAmino acids that directly contact DNA or CBFb, from crystal structures (Bravo et al, 2001; Tahirov et…”
BackgroundSelf-citationLucero, C. M. J., Vega, O. A., Osorio, M., Tapia, J. C., Antonelli, M., Stein, G. S., van Wijnen, A. J., & Galindo, M. A. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24218 · Cited by 123
“Inactivatingmutations or epigenetic silencing of Runx1 and Runx3 are associated to leukemia and gastric cancer, respectively (Song et al., 1999; Li et al., 2002; Cameron and Neil, 2004).”
BackgroundThe RUNX family in breast cancer: relationships with estrogen signaling
Chimge, N.-O., & Frenkel, B. (2012) · Oncogene · doi:10.1038/onc.2012.328 · Cited by 133
Babushok, D. V., Bessler, M., & Olson, T. S. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1115041 · Cited by 122
“RUNX1-associated familial platelet disorder with propensity to myeloid malignancy (FPD/AML, MIM# 601399) is an autosomal-dominant familial MDS/AML predisposition syndrome, caused by inherited mutations in the hematopoietic transcription factor RUNX1, associated with life-long moderate thrombocytopenia and platelet fun…”
BackgroundAML1 deletion in adult mice causes splenomegaly and lymphomas
Putz, G., Rosner, A., Nuesslein, I., Schmitz, N., & Buchholz, F. (2005) · Oncogene · doi:10.1038/sj.onc.1209136 · Cited by 132
“Haploinsufficiency of AML1 causes an autosomal dominant congenital platelet defect due to defective megakaryopoiesis and predisposes to the acquisition of additional mutations resulting in leukemia (Song et al., 1999; Sun and Downing, 2004).”
BackgroundKirwan, M., Walne, A. J., Plagnol, V., Velangi, M., Ho, A. Y. L., Hossain, U., Vulliamy, T., & Dokal, I. S. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.03.020 · Cited by 121
Arber, D. A., Borowitz, M. J., Cessna, M. H., Etzell, J. E., Foucar, K. K., Hasserjian, R. P., Rizzo, J. D., Theil, K. S., Wang, S. A., Smith, A. T., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0504-cp · Cited by 134
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
Rio‐Machín, A., Vulliamy, T., Hug, N., Walne, A. J., Tawana, K., Cardoso, S. R., Ellison, A., Pontikos, N., Wang, J., Tummala, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14829-5 · Cited by 130
Ferrando, A. A., & López-Otín, C. (2017) · Nature Medicine · doi:10.1038/nm.4410 · Cited by 120
“Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.”
BackgroundPRMT4 Blocks Myeloid Differentiation by Assembling a Methyl-RUNX1-Dependent Repressor Complex
Vu, L. P., Perna, F., Wang, L., Voza, F., Figueroa, M. E., Tempst, P., Erdjument-Bromage, H., Gao, R., Chen, S., Paietta, E., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.025 · Cited by 114
“Furthermore, RUNX1 point mutations are found in affected individuals with the inherited FPD/AML syndrome (familial platelet disorder with propensity to AML) (Song et al., 1999).”
Bluteau, D., Glembotsky, A. C., Raimbault, A., Balayn, N., Gilles, L., Rameau, P., Nurden, P., Alessi, M., Debili, N., Vainchenker, W., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422337 · Cited by 133
Inherited thrombocytopenias frequently diagnosed in adults
Balduini, C. L., Savoia, A., & Seri, M. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12196 · Cited by 119
Sun, W., & Downing, J. R. (2004) · Blood · doi:10.1182/blood-2003-12-4349 · Cited by 118
RUNX1/AML1: A Central Player in Hematopoiesis
Okuda, T., Nishimura, M., Nakao, M., & Fujitaa, Y. (2001) · International Journal of Hematology · doi:10.1007/bf02982057 · Cited by 118
Variation at theTERTlocus and predisposition for cancer
Baird, D. M. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239941000147x · Cited by 131
DePersia, A., Godley, L. A., & Churpek, J. E. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12346 · Cited by 128
Sahoo, S. S., Kozyra, E. J., & Wlodarski, M. W. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101197 · Cited by 109
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Sango, J., Carcamo, S., Sirenko, M., Maiti, A., Mansour, H. M., Ulukaya, G. B., Tomalin, L. E., Cruz‐Rodriguez, N., Wang, T., Olszewska, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08137-x · Cited by 122
“2d, we used a patient-derived RUNX1-FPD line harbouring a heterozygous RUNX1 mutation (NM_00100189: c.533-1G>T) as parental line 50,51 .”
Dicker, F., Haferlach, C., Kern, W., Haferlach, T., & Schnittger, S. (2007) · Blood · doi:10.1182/blood-2007-02-072595 · Cited by 127
“90 AMLM0 40–43,XY,del(5)(q13q31),der(8)t(8;12)(q21;q13), ins(11)(q13;?),-12, del(13)(q14),i(17)(q10) cp6 ,46,XY 20 — wt/wt wt ND ND”
Shimizu, R., Engel, J. D., & Yamamoto, M. P. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2348 · Cited by 126
Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis
Jacob, B., Osato, M., Yamashita, N., Wang, C. Q., Taniuchi, I., Littman, D. R., Asou, N., & Ito, Y. (2010) · Blood · doi:10.1182/blood-2009-07-232249 · Cited by 108
TEL-AML1 Corrupts Hematopoietic Stem Cells to Persist in the Bone Marrow and Initiate Leukemia
Schindler, J. W., Buren, D. V., Foudi, A., Krejci, O., Qin, J., Orkin, S. H., & Hock, H. R. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.04.019 · Cited by 122
“Accordingly, AML1 haploinsufficiency predisposes to leukemia (Kundu et al., 2005; Song et al., 1999).”
Transcription factor fusions in acute leukemia: variations on a theme
Scandura, J. M., Boccuni, P., Cammenga, J., & Nimer, S. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205315 · Cited by 132
“It is caused by nonsense and missense mutations that disrupt the DNA-binding activity or transcriptional activity of AML1 (Song et al., 1999).”
BackgroundZimonjic, D. B., Pollock, J. L., Westervelt, P., Popescu, N. C., & Ley, T. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13306 · Cited by 113
Genetic predispositions to childhood leukemia
Stieglitz, E., & Loh, M. L. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713498161 · Cited by 127
“12 [Song et al. 1999].”
BackgroundSelf-citationRecommendations for Surveillance for Children with Leukemia-Predisposing Conditions
Porter, C. C., Druley, T. E., Erez, A., Kuiper, R. P., Onel, K., Schiffman, J. D., Schneider, K. W., Scollon, S., Scott, H. S., Strong, L. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0428 · Cited by 115
Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7
Pastor, V. B., Sahoo, S. S., Boklan, J., Schwabe, G. C., Sarıbeyoğlu, E. T., Strahm, B., Lebrecht, D., Voß, M., Bryceson, Y. T., Erlacher, M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.180778 · Cited by 110
Fossett, N., Hyman, K., Gajewski, K. M., Orkin, S. H., & Schulz, R. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1635050100 · Cited by 128
Kirwan, M., Vulliamy, T., Marrone, A., Walne, A. J., Beswick, R., Hillmen, P., Kelly, R., Stewart, A., Bowen, D., Schonland, S. O., et al. (2009) · Human Mutation · doi:10.1002/humu.21115 · Cited by 109
“Arg201Gln), which was found to segregate with disease [Song et al., 1999].”
BackgroundMethodHighly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome
Kirsammer, G., Jilani, S., Liu, H., Davis, E., Gurbuxani, S., Le Beau, M. M., & Crispino, J. D. (2008) · Blood · doi:10.1182/blood-2007-04-085670 · Cited by 107
Latger‐Cannard, V., Philippe, C., Bouquet, A., Baccini, V., Alessi, M., Ankri, A., Bauters, A., Bayart, S., Cornillet‐Lefèbvre, P., Daliphard, S., et al. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0432-0 · Cited by 115
“The involved genes are RUNX1 (familial platelet disorder with propensity to develop acute myeloid leukaemia, FPD/AML, OMIM 601399) [1], CEBPA [2] and more recently GATA-2 [3] and ETV6 [4].”
Backgroundvan Bragt, M. P. A., Hu, X., Xie, Y., & Li, Z. (2014) · eLife · doi:10.7554/elife.03881 · Cited by 113
Inherited Predisposition to Acute Myeloid Leukemia
Godley, L. A. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.08.001 · Cited by 111
Metadata
- Authors
- Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., Loh, M., Felix, C., Roy, D.-C., Busque, L., Kurnit, D., Willman, C., Gewirtz, A. M., Speck, N. A., Bushweller, J. H., Li, F. P., Gardiner, K., Poncz, M., Maris, J. M., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Brown University (US)
- University of Pennsylvania (US)
- Leicester Royal Infirmary (GB)
- St Vincent Hospital (US)
- Hôpital Maisonneuve-Rosemont (CA)
- University of Michigan (US)
- University of New Mexico (US)
- Dartmouth College (US)
- University of Virginia (US)
- Harvard University (US)
- Roosevelt Institute (US)
- Corresponding author
- Gilliland, D. Gary
- ORCID
- Venue
- Nature Genetics
- Published
- 1999-10
- Volume
- 23
- Issue
- 2
- Pages
- 166-175
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1739103212
- Cited by
- 1,100
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 27 · 2023: 32 · 2022: 29 · 2021: 36 · 2020: 46 · 2019: 33 · 2018: 26 · 2017: 61 · 2016: 54 · 2015: 35 · 2014: 30 · 2013: 33 · 2012: 53
- FWCI
- 25.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29ai039536-04)
- National Cancer Institute (R01CA081932, R01-CA78545, R01 CA81932, R01CA078545)
- National Institute of Allergy and Infectious Diseases (R29 AI39536)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- RUNX1, haploinsufficiency, autosomal dominant inheritance, missense mutations, megakaryopoiesis, megakaryocyte colony formation, platelet disorders, chromosome 21q, nonsense mutation, intragenic deletion
- MeSH terms
- Amino Acid Sequence, Base Sequence, Blood Platelets, Chromosome Mapping, Colony-Forming Units Assay, DNA Mutational Analysis, DNA-Binding Proteins, Family Health, Female, Genotype, Hematopoiesis, Heterozygote, Humans, Male, Megakaryocytes, Molecular Sequence Data, Mutation, Pedigree, Proto-Oncogene Proteins, RNA, Sequence Homology, Nucleic Acid, Thrombocytopenia, Transcription Factors, Leukemia, Myeloid, Acute, Sequence Deletion, Sequence Homology, Amino Acid, In Situ Hybridization, Fluorescence, Microsatellite Repeats, Genetic Predisposition to Disease, Reverse Transcriptase Polymerase Chain Reaction, Core Binding Factor Alpha 2 Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.